🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "huge turning point" in the battle against increasingly resistant strains of the infection, according to scientists.

A Worldwide Challenge

Cases of gonorrhoea are increasing around the world, with figures suggesting in excess of 82 million infections annually. Especially elevated rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely advancement in the reality of growing infection rates, escalating drug resistance and the very limited therapeutic options presently on offer.”

Public health authorities are deeply concerned about the rise in drug-resistant strains. The World Health Organization has designated it as a "high-priority threat". Recent surveillance found that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Gain Authorization

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US FDA in December for combating gonorrhoea. This disease can lead to major issues, including infertility. Researchers believe that focused deployment of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This treatment, which is also used to treat urinary tract infections, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

This new treatment was the result of a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization signifies a significant shift in the management of multidrug-resistant gonorrhoea, which until now has been outpacing medical innovation.”

Research Study Outcomes and Worldwide Availability

Based on findings released by a major medical journal, zoliflodacin eradicated over nine in ten of cases of the STI. This puts it on an comparable level with the existing first-line therapy, which combines an injection and a pill. The research enrolled over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the ability to register and commercialise the drug in a wide range of regions with limited resources.

Medical professionals treating patients have expressed hope. Access to a single-dose, oral treatment such as this is hailed as a "revolutionary step" for gonorrhoea control. This is considered essential to lessen the impact of the illness for patients and to halt the transmission of highly drug-resistant gonorrhoea around the world.